Opportunity for Soleno Therapeutics Shareholders to Lead Class Action on Securities Fraud Claims
In a significant development for investors, Glancy Prongay Wolke & Rotter LLP has announced legal opportunities for shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who have suffered losses. The firm is inviting these affected investors to take the lead in a proposed class action lawsuit against the company due to alleged securities fraud that surfaced during clinical trials of its drug, DCCR.
The class action aims to address claims that Soleno misrepresented critical safety data regarding the DCCR Phase 3 clinical trial. Between March 26, 2025, and November 4, 2026, it is alleged that Soleno engaged in deceptive practices by downplaying evidence of safety issues associated with the drug. Notably, these concerns include excess fluid retention among trial participants, leading to potential risks that were not transparently reported.
Furthermore, the complaint asserts that the administration of DCCR for treating hyperphagia in individuals with Prader-Willi Syndrome (PWS) may pose greater safety hazards than Soleno disclosed. Consequently, the company’s assurances regarding DCCR's commercial viability are now in question, as the likelihood of adverse events post-launch has raised serious concerns about patient retention, prescriber acceptance, and regulatory actions.
For affected shareholders, this legal action presents a crucial opportunity to hold Soleno accountable for its purported misleading statements. The deadline for interested investors to join the lawsuit is set for May 5, 2026. If you have incurred losses on your Soleno investments within this timeframe, it is essential to reach out to the legal team to discuss your eligibility to join the lawsuit.
Shareholders are encouraged to contact Charles Linehan, Esq. at Glancy Prongay Wolke & Rotter LLP to learn more about the process. They can also gain insights into their rights and interests concerning this matter. The firm emphasizes that while taking action is encouraged, retaining legal counsel is not mandatory to participate in the class action.
As a reminder, this announcement from the law firm serves as an invitation to investors who believe they may have been misled by the company’s statements regarding its business status and clinical program. For more information, investors can reach out via email or phone, ensuring that pertinent details, such as contact information and shares purchased, are included in their inquiries.
While legal actions can often seem daunting, this moment serves as a call to action for those who have felt the effects of alleged corporate misconduct. Not only does it open the door for potential financial recovery, but it also stresses the importance of transparency and accountability within the biotech sector, particularly concerning claims made during critical drug trials.
Overall, investors play a vital role in upholding corporate integrity, and initiatives like this class action lawsuit empower them to seek justice and resolution in the face of potential malpractice. As developments unfold, it remains crucial for affected shareholders to stay informed and proactively engage with the ongoing legal proceedings.
The class action aims to address claims that Soleno misrepresented critical safety data regarding the DCCR Phase 3 clinical trial. Between March 26, 2025, and November 4, 2026, it is alleged that Soleno engaged in deceptive practices by downplaying evidence of safety issues associated with the drug. Notably, these concerns include excess fluid retention among trial participants, leading to potential risks that were not transparently reported.
Furthermore, the complaint asserts that the administration of DCCR for treating hyperphagia in individuals with Prader-Willi Syndrome (PWS) may pose greater safety hazards than Soleno disclosed. Consequently, the company’s assurances regarding DCCR's commercial viability are now in question, as the likelihood of adverse events post-launch has raised serious concerns about patient retention, prescriber acceptance, and regulatory actions.
For affected shareholders, this legal action presents a crucial opportunity to hold Soleno accountable for its purported misleading statements. The deadline for interested investors to join the lawsuit is set for May 5, 2026. If you have incurred losses on your Soleno investments within this timeframe, it is essential to reach out to the legal team to discuss your eligibility to join the lawsuit.
Shareholders are encouraged to contact Charles Linehan, Esq. at Glancy Prongay Wolke & Rotter LLP to learn more about the process. They can also gain insights into their rights and interests concerning this matter. The firm emphasizes that while taking action is encouraged, retaining legal counsel is not mandatory to participate in the class action.
As a reminder, this announcement from the law firm serves as an invitation to investors who believe they may have been misled by the company’s statements regarding its business status and clinical program. For more information, investors can reach out via email or phone, ensuring that pertinent details, such as contact information and shares purchased, are included in their inquiries.
While legal actions can often seem daunting, this moment serves as a call to action for those who have felt the effects of alleged corporate misconduct. Not only does it open the door for potential financial recovery, but it also stresses the importance of transparency and accountability within the biotech sector, particularly concerning claims made during critical drug trials.
Overall, investors play a vital role in upholding corporate integrity, and initiatives like this class action lawsuit empower them to seek justice and resolution in the face of potential malpractice. As developments unfold, it remains crucial for affected shareholders to stay informed and proactively engage with the ongoing legal proceedings.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.